



Clinical Trial and Consulting Services

May Newsletter



Volume 11, Issue 5

We are recruiting for CRAs in the US, UK, France, Belgium, Sweden, Germany, Poland, Italy and the Netherlands!

Upcoming Medical Meetings CTI will be Attending ...

American Society of Clinical Oncology Annual Meeting
Chicago, IL
May 31 – June 4

DIA 2013 49th Annual Meeting
Boston, MA
June 23 – 27

If you are interested in scheduling a meeting with CTI, please contact Nick Schatzman at 513-598-9290 or via email at nschatzman@ctifacts.com

Employee Update

Congratulations to the following CTI employees recently promoted:

Matt Hodskins - Assistant

The Case for Continued Drug Development in Solid Organ Transplantation

Significant progress has been made in reducing the incidence of acute rejection for solid organ transplantation. Since the introduction of cyclosporine, many new therapies and approaches to immunosuppression have evolved, from induction therapy regimes pre-transplant to minimization strategies post-transplant. With these advances, short-term patient and graft outcomes have greatly improved, leading one to question any additional benefits of developing new compounds in this unique therapeutic area.

However, while great improvements have been noted, long term outcomes have not changed to the same extent. Unmet medical needs remain in the areas of delayed graft function, ischemia reperfusion injury, highly sensitized recipients, long-term toxicities of maintenance immunosuppressive agents, antibody mediated rejection, and the prophylaxis and treatment of opportunistic infections.

Further factors supportive of development in transplantation are experienced investigators willing to partner with the pharmaceutical industry, identified clinical endpoints, and the favorable financial reimbursement and market for these drugs, even with generics now readily available.

Many sponsors have already considered transplantation as an important part of their clinical development platforms for new immunologic compounds among other areas of rheumatoid arthritis, psoriasis, multiple sclerosis, lupus, and others.

As a therapeutic leader in the Transplantation and Immunology market, CTI has strong relationships and extensive experience working with many compounds in all phases of drug development in transplantation.

Director, Project and Proposal Management

Robert McRae – Study Manager

Please welcome the newest additions to CTI:

Guillermo Revilla – Sr. Clinical Research Associate, Spain

Michael Romes – Research Associate

Paula Ulsh, BSN – Assistant Director, Medical & Scientific Affairs

Quick Links...

[Our Website](#)

[Email](#)

[Join Our Mailing List!](#)

For more information contact:

Catherine E. Klose, BSN, MPH
Senior Director, Business Development
CTI Clinical Trials and Consulting Services
10123 Alliance Road
Cincinnati, OH 45242
(513)598-9290 office



About CTI

CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI's focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious diseases, hematology, cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program's success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe and South America.